Drug intelligence / Profile preview

BP22042013

Development stage: Unknown
Lead developer: Spanish Foundation for Neurometrics
Modality: Peptides, Recombinant Proteins and Enzymes
Administration: Oral

Overview

BP22042013 is a specialized dietary intervention developed by the Spanish Foundation for Neurometrics Development, specifically designed for children aged 7 to 12 with Attention Deficit Hyperactivity Disorder (ADHD). The regimen, often referred to as the BrainProtein diet, consists of a 2,000-kilocalorie daily intake structured with 107 grams of protein, 144 grams of fat, and 60 grams of carbohydrates. This high-protein, low-carbohydrate approach includes two daily protein shakes and is intended to improve behavior and neurobiological markers, such as brain connectivity, by altering the availability of amino acids and other nutrients essential for neurotransmitter synthesis and neurological function.

Other names: BrainProtein

Beyond the preview

Go deeper on BP22042013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BP22042013.

Explore the full profile